High TCIRG1-expressing KIRC patients may incur a greater risk of tumor progression, and by the diversity of immune cell infiltration levels and status between the high- and low-TCIRG1 expression subgroups, patients with high TCIRG1 expression may receive a more precise immunotherapeutic strategy. This evidence concerns the gene TCIRG1 and neoplasm.